← All trials
NCT04694586
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2020
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2026
- First posted
- Jan 5, 2021
- Last posted
- Jan 5, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Linkoping UniversityLead sponsor
- Karolinska InstituteCollaborator
- Linkoping UniversityReponsible party - principal investigator
- Linkoping UniversityOverall official - principal investigator
- Linkoping UniversityCollaborator
- Ryhov County HospitalCollaborator
- Kalmar County HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.